21 / 26
Immunology 2018
J u l y 0 5 - 0 7 , 2 0 1 8
V i e n n a , A u s t r i a
Page 58
Journal of Clinical Immunology and Allergy
ISSN 2471-304X
1 5
t h
I n t e r n a t i o n a l C o n f e r e n c e o n
Immunology
A
n individual’s antibody profile or immunome is stable over years but can
change in respect to pathological changes as well as these changes can
be triggered by vaccination/ immunization or different therapeutic intervention.
Antibody profiling on high density protein and peptide arrays has been shown
to elucidate pathophysiological alterations in various indications like auto-
immune, cancerous, and neurological disease, as well as in allergy and
infectious disease. Protein-arrays are usually generated using recombinant
expression, and have limited flexibility – but can be customized when proteins
are available. Peptide-arrays can be easily customized to present proteins
deduced from sequences, without the need of protein-expression. We have
setup immunomics discovery technologies using protein- and peptide-
microarrays (presenting 32000 spots or up to 6 million peptides, respectively)
as well as targeted multiplexed technologies for validation of findings. These
are all customizable and affordable even when discovery studies are done
with a small number of samples. In line with the different technologies we
have established and optimized bioinformatics and laboratory methods and
can provide complete workflows from design, experimental setup and sample
analysis till data-analysis. This is also true when we have lower multiplexed
technologies available providing targeted micro-arrays (presenting hundreds-
thousands antigens) as well as bead-arrays in an up to 500-plexed format for
marker-refinement and confirmation. For broader validation and clinical studies
we have both micro- and bead-array technologies established for analyzing
large series of samples in 96-well microtiter-plates in medium-plexed assays.
We have established and optimized different methods and combined these to a
full workflow for providing modules as well as the entire pipeline for antibody-
based analysis and diagnostics, which can be conducted with 10µl amounts of
serum or plasma as well as using other body fluids like saliva.
Biography
Andreas Weinhausel is a Biotechnologist and Specialist in
Human Genetics. He has more than 20 years’ experience in
Molecular Diagnostics. He has worked at the Children’s Cancer
Research Institute, Vienna (1995-2004); he is specialized in
Human Molecular Genetics Diagnostics of Syndromal and
HereditaryNeoplasticDisease. Since 2004, he has beenworking
in the Molecular Diagnostics unit at the AIT-Austrian Institute of
Technology and his focus is on DNA-methylation and protein
biomarker development for cancerous and other systemic
human disease using omics discovery and high throughput
validation technologies. He is also an Associate Professor for
Molecular Biology at the University of Natural Resources and
Applied Life Sciences, Vienna.
andreas.weinhaeusel@ait.ac.atImmunomics technologies using protein and peptide
microarrays – for antibody profiling
Andreas Weinhausel, Regina Soldo, Peter Hettegger, Silvia
Schonthaler, Lisa Milchram, Ronald Kulovics, Manuela Hofner,
Christa Noehammer, Stephan Pabinger and Klemens Vierlinger
Center for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Austria
Andreas Weinhausel et al., Insights Allergy Asthma Bronchitis 2018, Volume: 4
DOI: 10.21767/2471-304X-C1-002